中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2009年
21期
62-63
,共2页
精神分裂症%维思通%卓菲%疗效
精神分裂癥%維思通%卓菲%療效
정신분렬증%유사통%탁비%료효
Schizophrenia%Weisitong%Zhuofei%Curative effect
目的:通过分析合资维思通与国产卓菲治疗精神分裂症的临床效果,根据家境和个体情况选取药物.方法:将70例精神分裂症患者随机分为两组,经8周治疗,以CCMD-3精神分裂症的诊断标准、PANSS评定疗效,TESS评定副作用.结果:两组治疗后PANSS评分与治疗前比较,均有显著性差异;治疗后随治疗时间延长而下降,副作用少,说明两药治疗精神分裂症效果显著.结论:维思通疗效比卓菲好,起效快;不良反应卓菲比维思通高;但两者的疗效和副作用比较均无显著性差异,而价格有差别.临床可根据患者经济状况和个体差异来选择使用.
目的:通過分析閤資維思通與國產卓菲治療精神分裂癥的臨床效果,根據傢境和箇體情況選取藥物.方法:將70例精神分裂癥患者隨機分為兩組,經8週治療,以CCMD-3精神分裂癥的診斷標準、PANSS評定療效,TESS評定副作用.結果:兩組治療後PANSS評分與治療前比較,均有顯著性差異;治療後隨治療時間延長而下降,副作用少,說明兩藥治療精神分裂癥效果顯著.結論:維思通療效比卓菲好,起效快;不良反應卓菲比維思通高;但兩者的療效和副作用比較均無顯著性差異,而價格有差彆.臨床可根據患者經濟狀況和箇體差異來選擇使用.
목적:통과분석합자유사통여국산탁비치료정신분렬증적림상효과,근거가경화개체정황선취약물.방법:장70례정신분렬증환자수궤분위량조,경8주치료,이CCMD-3정신분렬증적진단표준、PANSS평정료효,TESS평정부작용.결과:량조치료후PANSS평분여치료전비교,균유현저성차이;치료후수치료시간연장이하강,부작용소,설명량약치료정신분렬증효과현저.결론:유사통료효비탁비호,기효쾌;불량반응탁비비유사통고;단량자적료효화부작용비교균무현저성차이,이개격유차별.림상가근거환자경제상황화개체차이래선택사용.
Objective: To discuss the clinical effect of joint-stock Risperidone (Weisitong) and domestic Risperidone (Zhuofei) on schizophrenia. The choosing of the two medicaments was based on the family financial situation and individual difference. Methods: 70 patients with schizophrenia were randomly divided into two groups, after 8 weeks of treatment, all the patients were selected in accordance with the CCMD-3 diagnosis standard. The clinical effect of patients were measured by the PANSS and the side effects were evaluated with the TESS. Results: There was significant differences on PANSS between pre- treatment and post-treatment. The score declines and the side effect decreased with the prolonging of time. This showed that the two medicaments had evident clinic efficacy on schizophrenia. ConchLsion: Joint-stock Risperidone show better effect and faster effect than domestic Risperidone, but the side effects by contraries. There is not significant differences on curative effect and side effect, but the price show difference. So we can choose anyone according to the economy status and individual difference.